America post-Dobbs will get even more contentious

Plus more health news |

Email not displaying correctly? View it in your browser.

America's second year after Dobbs will be even more contentious By Haley Weiss Health Reporter     It’s been a year since the power to determine abortion access was turned over to states by the Supreme Court. Since then, a new chapter of one of the country’s most heated fights has been playing out in 50 different ways, with some states passing legislation to protect the right to abortion; others effectively outlawing the procedure; and still others falling somewhere in between. As the country moves into its second year without the protections of Roe v. Wade, here are four of the key approaches anti-abortion activists are likely to prioritize: Electoral maneuvering: Legal challenges brought directly to judges, like the Texas lawsuit seeking to overturn the U.S. Food and Drug Administration’s approval of the abortion medication mifepristone are likely to continue in the coming year, says Skye Perryman, president and CEO of Democracy Forward. Some conservative states are also making it more difficult for abortion-related measures to make it onto ballots. Unorthodox legal strategies: Conservative groups are looking for loopholes and statutes in existing laws that could be applied to abortion supplies and providers. One such group, Students for Life of America, has filed petitions arguing that the medication used in abortions violate U.S. wastewater regulations. Expanding conservative support networks: Crisis pregnancy centers, which are often run by Christian groups and typically work to prevent abortion rather than provide care, outnumber clinics that provide abortion three to one in the U.S. Documents from leading anti-abortion organizations have stressed their desire to spread the reach of these facilities and associated homes for new at-risk mothers. Criminalization of pregnancy and reproductive care: 38 states currently allow prosecutors to charge pregnant women with a variety of crimes under fetal protection laws. Expect to see more headline-making cases of both pregnant women and providers being prosecuted by state attorneys general. READ MORE Share This Story

What Else to Read Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns By Matthew Griffin / Bloomberg The drugmaker will stop work on lotiglipron based on data from phase 1 clinical trials and lab measurements showing elevated enzyme levels. Read More » 3M’s Historic $10 Billion ‘Forever Chemical’ Payout Is Just The Tip of the PFAS Iceberg By Jeffrey Kluger 'Forever chemical' manufacturers are facing thousands of lawsuits seeking compensation for cleaning up local land and water supplies. Read More » More Weight Loss Drugs Are Coming, And They Could Be Even More Effective By Alice Park New data from Eli Lilly show two of its anticipated weight-loss drugs—Mounjaro and orforglipron—worked in recent studies. Read More » Scientists Say They've Reached Turning Point in Cancer Research With Vaccines By Carla K. Johnson / AP Scientists say research has reached a turning point, with many predicting more cancer vaccines will be out in five years. Read More » Why Older People Love Pickleball So Much By Holly Burns The sport is a low-impact way to get moving, plus an avenue to socialization. Read More »

ONE LAST READ Inside the secretive world of penile enlargement While the pharmaceutical industry has made billions of dollars from treating erectile dysfunction, penis enlargement remains a niche industry, dominated by the devices marketed by a single urologist. Writing for the New Yorker and ProPublica, Ava Kofman explores the poorly regulated world of penile implants and the devastating harm to patients whose experience with them has gone horribly wrong. Read More »

If you were forwarded this and want to sign up to receive it daily, click here. Today's newsletter was written by Haley Weiss and edited by Oliver Staley.

Want more from TIME? Sign up for our other newsletters. Subscribe to TIME

TIME may receive compensation for some links to products and services in this email. Offers may be subject to change without notice.   Connect with TIME via Facebook | Twitter | Newsletters       UNSUBSCRIBE     PRIVACY POLICY     YOUR CALIFORNIA PRIVACY RIGHTS   TIME Customer Service, P.O. Box 37508, Boone, IA 50037-0508   Questions? Contact health@time.com   Copyright © 2023 TIME USA, LLC. All rights reserved.